Michael I Fingerhood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6986282/publications.pdf

Version: 2024-02-01

66 papers 1,786 citations

257429 24 h-index 289230 40 g-index

66 all docs

66
docs citations

66 times ranked 1756 citing authors

#	Article	IF	CITATIONS
1	Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year. Journal of Substance Abuse Treatment, 2009, 37, 426-430.	2.8	129
2	ONE-, THREE-, AND SIX-MONTH OUTCOMES AFTER BRIEF INPATIENT OPIOID DETOXIFICATION. American Journal of Drug and Alcohol Abuse, 2001, 27, 19-44.	2.1	96
3	Opioid agonist treatment and fatal overdose risk in a stateâ€wide US population receiving opioid use disorder services. Addiction, 2020, 115, 1683-1694.	3.3	95
4	A RANDOMIZED TRIAL OF EMPLOYMENTâ€BASED REINFORCEMENT OF COCAINE ABSTINENCE IN INJECTION DRUG USERS. Journal of Applied Behavior Analysis, 2007, 40, 387-410.	2.7	92
5	Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. Journal of Substance Abuse Treatment, 2019, 103, 1-8.	2.8	80
6	Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug and Alcohol Dependence, 2017, 178, 512-518.	3.2	79
7	Substance Abuse in Older People. Journal of the American Geriatrics Society, 2000, 48, 985-995.	2.6	66
8	Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial. Drug and Alcohol Dependence, 2012, 120, 48-54.	3.2	64
9	Substance-Use Disorders in Later Life. New England Journal of Medicine, 2018, 379, 2351-2360.	27.0	56
10	Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore, Maryland. International Journal of Drug Policy, 2019, 68, 86-92.	3.3	52
11	Employmentâ€based reinforcement of adherence to depot naltrexone in unemployed opioidâ€dependent adults: a randomized controlled trial. Addiction, 2011, 106, 1309-1318.	3.3	51
12	Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural Versus an Urban Setting. Journal of Substance Abuse Treatment, 2016, 71, 1-7.	2.8	47
13	Overcoming Medication Stigma in Peer Recovery: A New Paradigm. Substance Abuse, 2018, 39, 404-409.	2.3	46
14	An Exploration of Emergency Physicians' Attitudes Toward Patients With Substance Use Disorder. Journal of Addiction Medicine, 2018, 12, 132-135.	2.6	46
15	Article Commentary: Demystifying Buprenorphine Misuse: Has Fear of Diversion Gotten in the Way of Addressing the Opioid Crisis?. Substance Abuse, 2019, 40, 148-153.	2.3	46
16	Brief Opioid Overdose Knowledge (BOOK): A Questionnaire to Assess Overdose Knowledge in Individuals Who Use Illicit or Prescribed Opioids. Journal of Addiction Medicine, 2016, 10, 314-323.	2.6	45
17	Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users Experimental and Clinical Psychopharmacology, 2013, 21, 74-83.	1.8	41
18	Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. Drug and Alcohol Dependence, 2015, 157, 143-149.	3.2	41

#	Article	IF	Citations
19	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD. PLoS ONE, 2019, 14, e0224686.	2.5	38
20	A Randomized Clinical Trial of a Therapeutic Workplace for Chronically Unemployed, Homeless, Alcohol-Dependent Adults. Alcohol and Alcoholism, 2011, 46, 561-569.	1.6	35
21	Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial. AIDS and Behavior, 2019, 23, 2337-2346.	2.7	34
22	Adapting a Low-threshold Buprenorphine Program for Vulnerable Populations During the COVID-19 Pandemic. Journal of Addiction Medicine, 2021, 15, 364-369.	2.6	32
23	Randomized controlled trial of a computerized opioid overdose education intervention. Drug and Alcohol Dependence, 2017, 173, S39-S47.	3.2	30
24	Lessons from COVID 19: Are we finally ready to make opioid treatment accessible? Journal of Substance Abuse Treatment, 2020, 117, 108074.	2.8	26
25	Monetary incentives to reinforce engagement and achievement in a job-skills training program for homeless, unemployed adults. Journal of Applied Behavior Analysis, 2013, 46, 582-591.	2.7	24
26	An intensive assessment of alcohol use and emergency department utilization in homeless alcohol-dependent adults. Drug and Alcohol Dependence, 2017, 178, 28-31.	3.2	24
27	What Patients with Addiction Disorders Need from Their Primary Care Physicians: A Qualitative Study. Substance Abuse, 2016, 37, 349-355.	2.3	23
28	A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Substance Abuse, 2001, 22, 193-199.	2.3	21
29	Change in Medical Student Attitudes Toward Patients with Substance Use Disorders After Course Exposure. Academic Psychiatry, 2018, 42, 283-287.	0.9	20
30	Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost. Population Health Management, 2019, 22, 292-299.	1.7	20
31	Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Care Professionals. JAMA Network Open, 2022, 5, e2146971.	5.9	20
32	Opioid Overdose History, Risk Behaviors, and Knowledge in Patients Taking Prescribed Opioids for Chronic Pain. Pain Medicine, 2017, 18, pnw228.	1.9	19
33	Effects of incentives for naltrexone adherence on opiate abstinence in heroinâ€dependent adults. Addiction, 2017, 112, 830-837.	3.3	19
34	A Novel Community-Based Buprenorphine Program. Journal of Addiction Medicine, 2014, 8, 40-46.	2.6	16
35	The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial. Drug and Alcohol Dependence, 2019, 197, 220-227.	3.2	16
36	Refractory ventricular tachycardia with flecainide. American Heart Journal, 1986, 112, 174-175.	2.7	15

#	Article	IF	Citations
37	Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes Psychology of Addictive Behaviors, 2015, 29, 270-276.	2.1	15
38	Abstinence-contingent wage supplements to promote drug abstinence and employment: a randomised controlled trial. Journal of Epidemiology and Community Health, 2020, 74, 445-452.	3.7	15
39	Smartphone-based incentives for promoting adherence to antiretroviral therapy: A randomized controlled trial. Preventive Medicine Reports, 2021, 21, 101318.	1.8	15
40	Abstinence Incentive Effects in a Short-Term Outpatient Detoxification Program Experimental and Clinical Psychopharmacology, 2004, 12, 262-268.	1.8	13
41	Behavioural health interventions in the Johns Hopkins Community Health Partnership: Integrated care as a component of health systems transformation. International Review of Psychiatry, 2014, 26, 648-656.	2.8	13
42	Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults. Journal of Substance Abuse Treatment, 2018, 85, 38-44.	2.8	11
43	Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study. Journal of Substance Abuse Treatment, 2018, 85, 56-60.	2.8	10
44	Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder. Drug and Alcohol Dependence, 2021, 225, 108786.	3.2	10
45	Professional Demeanor of Chronically Unemployed Cocaine-Dependent Methadone Patients in a Therapeutic Workplace. Substance Use and Misuse, 2007, 42, 1141-1159.	1.4	9
46	Opioid agonist treatment is highly protective against overdose death among a U.S. statewide population of justice-involved adults. American Journal of Drug and Alcohol Abuse, 2021, 47, 117-126.	2.1	9
47	Financial incentives promote engagement in employment services for unemployed adults in treatment for opioid use disorder. Drug and Alcohol Dependence, 2020, 212, 107982.	3.2	8
48	Personality Characteristics of Treatment-Seeking HIV+ Pregnant Drug Dependent Women. Journal of Addictive Diseases, 1998, 17, 91-111.	1.3	7
49	Five-Year Outcomes of a Cohort of HIV-Infected Injection Drug Users in a Primary Care Practice. Journal of Addictive Diseases, 2006, 25, 33-38.	1.3	7
50	Evaluation of a Computer-Based HIV Education Program for Adults Living with HIV. AIDS and Behavior, 2019, 23, 3152-3164.	2.7	7
51	Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients Experimental and Clinical Psychopharmacology, 2014, 22, 75-85.	1.8	5
52	Coaching Primary Care Clinicians in the Ambulatory Setting: Direct Observation and Deliberate Practice. Family Medicine, 2019, 51, 830-835.	0.5	5
53	Effects of incentivizing viral suppression in previously incarcerated adults living with HIV. HIV Research and Clinical Practice, 2020, 21, 1-10.	1.1	4
54	How Community Health Workers Can Affect Health Care. JAMA Internal Medicine, 2018, 178, 1643.	5.1	3

#	Article	IF	CITATIONS
55	Effects of incentives on viral suppression in people living with HIV who use cocaine or opiates. Drug and Alcohol Dependence, 2020, 212, 108000.	3.2	3
56	Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting. American Journal on Addictions, 2022, 31, 256-260.	1.4	3
57	Studying how state health services delivery policies can mitigate the effects of disasters on drug addiction treatment and overdose: Protocol for a mixed-methods study. PLoS ONE, 2021, 16, e0261115.	2.5	3
58	Impact of hepatitis C status on 20-year mortality of patients with substance use disorders. Addiction Science & Edinical Practice, 2015, 10, 20.	2.6	2
59	The effects of the therapeutic workplace and heavy alcohol use on homelessness among homeless alcohol-dependent adults. Drug and Alcohol Dependence, 2016, 168, 135-139.	3.2	2
60	Influencing Career Choice and So Much More: The Role Model Clinician in 2018. Journal of Graduate Medical Education, 2018, 10, 155-156.	1.3	2
61	â€~I had a gun'. Journal of General Internal Medicine, 2000, 15, 143-143.	2.6	1
62	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0
63	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0
64	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0
65	More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD., 2019, 14, e0224686.		0
66	Clinical Excellence in HIV Care. Southern Medical Journal, 2015, 108, 350-3.	0.7	0